KK-2269

N/A

Report date: 2024/07/02 16:43:00

Base Information

Drug NameKK-2269
Drug Alias NameKK2269KK-2269
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionEpithelial cell adhesion molecule modulatorsTumor necrosis factor receptor superfamily member 5 agonists
TargetsTumor necrosis factor receptor superfamily member 5Epithelial cell adhesion molecule
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKyowa Kirin Inc
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Kirin IncKyowa Kirin Co Ltd
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A